Latest annual review on pipeline drugs for adults and children, strategies for cure and prevention for HIV, HCV, TB and vaccine research.

The guide provides a summary of safety and efficacy data for drugs currently in use to treat TB. It also highlights research and access gaps for advocacy by activists, clinicians, and others working in TB.

Research dollars drop just as old disease grows more difficult to treat.

Rifapentine is an FDA-approved drug for treating tuberculosis that forms part of a regimen for TB infection. Despite clear efficacy, rifapentine's utilization by US TB programs has been lower than expected. The Treatment Action Group and the Consortium to Respond Effectively to the AIDS/TB Epidemic partnered with the National Tuberculosis Controllers Association to conduct a survey among program managers to investigate barriers to rifapentine use in order to inform ongoing advocacy efforts to increase rifapentine access. Results of the survey were recently presented as a poster at the 18th Annual Conference of the Union North America Region annual meeting.

Community groups express concern for AstraZeneca's departure from tuberculosis and urge the company to ensure continued investment in the field.

Comment on Guidance for industry on pulmonary tuberculosis: Developing drugs for treatment.

To prioritize an agenda for implementing TB diagnostics that centers upon the patient with TB symptoms and highlights patient well-being and cure.

Re: GeneXpert machine and Xpert MTB/RIF cartridge pricing, extended warranties and business in Russia and the People’s Republic of China

Leading doctors, advocacy groups, medical organizations and U.S. TB programs commend Sanofi U.S. commitment to reduce the price of tuberculosis drug rifapentine.

Sanofi U.S. has committed to lowering the price of rifapentine (Priftin) to $32 per 32-tablet blister pack in January 2014.